secwatch.observer — SEC 8-K summary
======================================

Issuer:     BriaCell Therapeutics Corp. (BCTX)
CIK:        0001610820
Form:       8-K
Filed at:   2026-06-26T20:05:40+00:00
Accession:  0001493152-26-030286
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BriaPro subsidiary reports 9-month net loss of $712K; going concern uncertainty
-------------------------------------------------------------------------------

- Net loss for 9 months ended April 30, 2026: $712,236, vs $519,804 in prior-year period.
- Accumulated deficit of $1,892,661; cash $299,950 vs $1 at July 31, 2025.
- Acquired sCD80 license from parent BriaCell for 23,972,589 shares valued at $846,532.
- Due to related parties (BriaCell) $2,093,345; going concern depends on parent financing.
- R&D expenses $649,991; granted 7,189,000 RSUs to directors on April 1, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1610820/000149315226030286/0001493152-26-030286-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1610820/000149315226030286/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-030286

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer